ClinicalTrials.gg
CompletedNCT06081530Updated Apr 9, 2025

A Study in Healthy Men to Test How Well Different Doses of BI 3802876 Are Tolerated

A Phase 1 interventional study of BI 3802876 and Placebo matching BI 3802876 in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Belgium. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-09.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The main objective of this trial is to investigate the safety, tolerability, and pharmacokinetics of BI 3802876 when administered in different doses in healthy male volunteers. The primary objective is to descriptively assess the frequency of drug-related adverse events (AEs) in subjects treated with BI 3802876, as compared to placebo. The secondary objective is to descriptively assess pharmacokinetic parameters.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (temperature, blood pressure, pulse), 12-lead (ECG), and clinical laboratory tests
  2. Age of ≥18 to ≤55 years at screening
  3. (BMI) of ≥ 19.0 to ≤ 28.0 kg/m2 at screening. A minimum body weight of 65 kg at screening
  4. Signed and dated written prior to admission to the study, in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-GCP) and local legislation

Exclusion criteria

Exclusion Criteria:

  1. Any finding in the medical examination (including blood pressure (BP), pulse rate, or ) deviating from normal and assessed as by the investigator
  2. Three repeated measurements of systolic BP outside the range of 80 to 130 mm Hg, diastolic BP outside the range of 50 to 80 millimetre of mercury (mmHg), or pulse outside the range of 45 to 90 beats per minute.
  3. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance.
  4. Any evidence of a concomitant disease assessed as clinically relevant by the investigator

Further exclusion criteria apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Part A: BI 3802876 dose group 1

    Drug: BI 3802876

  • Experimental
    Part A: BI 3802876 dose group 2

    Drug: BI 3802876

  • Experimental
    Part A: BI 3802876 dose group 3

    Drug: BI 3802876

  • Experimental
    Part A: BI 3802876 dose group 4

    Drug: BI 3802876

  • Experimental
    Part A: BI 3802876 dose group 5

    Drug: BI 3802876

  • Experimental
    Part A: BI 3802876 dose group 6

    Drug: BI 3802876

  • Placebo comparator
    Part A: Placebo

    Drug: Placebo matching BI 3802876

  • Experimental
    Part B: BI 3802876

    Drug: BI 3802876

  • Placebo comparator
    Part B: Placebo

    Drug: Placebo matching BI 3802876

Interventions

  • DrugBI 3802876

    BI 3802876

  • DrugPlacebo matching BI 3802876

    Placebo matching BI 3802876

06

What researchers measure

Primary outcomes

  1. Part A and Part B: Occurrences of any drug-related AEs between first drug administration (BI 3802876 or placebo) and end of the residual effect period (REP)

    Time frame: up to Day 35 for Part A and up to Day 117 for Part B

Secondary outcomes

  1. Part A: Area under the concentration-time curve of the analyte in serum over the time interval from 0 extrapolated to infinity (AUC0-∞)

    Time frame: up to Day 35

  2. Part A: Maximum measured concentration of the analyte in serum (Cmax)

    Time frame: up to Day 35

  3. Part B: Area under the concentration-time curve of the analyte in serum over the dosing interval tau at steady state, if steady state can be reasonably assumed (AUCτ,ss)

    Time frame: up to Day 117

  4. Part B: Maximum measured concentration of the analyte in serum at steady state, if steady state can be reasonably assumed (Cmax,ss)

    Time frame: up to Day 117

07

Study locations

1 site
  • SGS Life Science Services - Clinical Research
    Edegem, 2650, Belgium
08

References and documents

Related links

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Mar 2025, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2023
First posted
Oct 13, 2023
StartActual
Oct 27, 2023
Primary completionActual
Mar 20, 2025
CompletionActual
Mar 20, 2025
Last update
Apr 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06081530
Responsible party
Sponsor
First posted
Oct 13, 2023
Start date
Oct 27, 2023
Primary completion
Mar 20, 2025
Completion
Mar 20, 2025
Last update
Apr 9, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion